Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
The combined entity will have 12 hospitals with 3,666 beds
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
